Juvenile Arthritis News

The Childhood Arthritis and Rheumatology Research Alliance developed the following three treatment plans for patients with juvenile dermatomyositis and persistent skin rash: intravenous immunoglobulin; mycophenolate mofetil; and cyclosporine.

Tocilizumab therapy was effective in patients with severe juvenile idiopathic arthritis-associated uveitis who previously failed conventional immunosuppressive drugs with at least one anti- tumor necrosis factor agent, according to this study.

Compared with methotrexate monotherapy, tumor necrosis factor inhibitor monotherapy or used in combination with methotrexate were not associated with an increased risk for infection in patients with juvenile idiopathic arthritis, according to recently published findings.

The FDA has approved Amjevita, a biosimilar to Humira, according to an FDA press release.

Novartis announced the FDA granted three simultaneous approvals for the expanded use of Ilaris to treat three distinct types of periodic fever syndromes.

Recently published results showed comparable improvements in patients with severe refractory juvenile idiopathic arthritis-related uveitis when treated with abatacept as either a first-line biological treatment or after one or more anti-tumor necrosis factor agents.

The Pharmaceutical Research and Manufacturers of America and the Lupus Foundation of America released a report that showed biopharmaceutical research companies in the United States have 311 medicines and vaccines in clinical trials or pending review by the FDA for patients with autoimmune disease.

An interim analysis of individuals with chronic pain living in the United Kingdom showed a possible link between weather conditions and chronic pain.

Among patients with juvenile idiopathic arthritis, use of ultrasound may increase the accuracy when assessing subtalar joint involvement, according to results.

Recently published results showed that although young individuals with inflammatory arthritis place value on treatment that helps them live a normal life, there are profound and lasting emotional, social and vocational consequences of treatment.